In many tumors, it has been reported that the expression of Glo1 is higher in more aggressive and invasive cells than in less aggressive tumor cells, as described in: PC3 and LNCaP cell lines of prostate cancer, MDA and MCF-7 cell lines of breast cancer, skin carcinomas and skin benign neoplasms, respectively (63–65). This evidence concerns the gene GLO1 and breast carcinoma.